Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study

Authors

X. Pivot, J.P. Spano, M. Espie, P. Cottu, C. Jouannaud, V. Pottier, L. Moreau, J.M. Extra, A. Lortholary, P. Rivera, D. Spaeth, H. Attar-Rabia, C. Benkanoun, L. Dima-Martinez, N. Esposito, J. Gligorov